Rob has been counsel in the following transactions:
- Arizona Metals Corp. in its $27,077,090 bought deal public offering of common shares.
 - Kernaghan & Partners Ltd. as lead agent and sole bookrunner in a brokered private placement offering of flow-through units of Golden Spike Resources Corp.
 - Acted as Canadian counsel to Psyence Group Inc, a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, and Psyence Biomedical Ltd., in their business combination agreement with Newcourt Acquisition Corp., a special purpose acquisition company (SPAC). The combination resulted in Psyence Biomedical Ltd. listing on NASDAQ as a public company that leverages natural psilocybin in the treatment of palliative care.
 - Orford Mining Corporation in its sale to Alamos Gold Inc. pursuant to a court approved plan of arrangement.
 - Mink Ventures Corporation in its closing of Qualifying Transaction and Concurrent Financing, completed by way of a property option agreement which provides Mink Ventures with an option to acquire an 80% interest in the Montcalm Property. In connection with the Qualifying Transaction, Mink Ventures also completed a private placement offering of subscription receipts raising gross proceeds of $891,876.
 - XAU Resources Inc. in its closing of a Qualifying Transaction and Concurrent Financing, competed by way of a property option agreement which provides XAU Resources with an option to acquire a 100% interest in the Noseno Property. In connection with the Qualifying Transaction, XAU Resources also completed a private placement offering of subscription receipts raising gross proceeds of $1M.
 - Orford Mining Corp. in its closing of a $4.4M non-brokered private placement, with each hard dollar unit consisting of one common share and one-half of a common share purchase warrant.
 - StageZero Life Sciences Ltd. in the closing of a $4.2M private placement of its Common Shares and Warrants to purchase Common Shares with institutional investors.
 - PNG Copper Inc. in its closing of the third and final tranche of a $1.12M private placement, with each unit consisting of one Class A common share in the capital of the Company and one Share purchase warrant.
 - Orford Mining Corp. in its closing of a $1.92M non-brokered private placement of: flow-through units and hard dollar units, with flow-through units consisting of one common share and one-half of a common share purchase warrant.
 - Psyence Group Inc. in its listing on the Canadian Securities Exchange; including its reverse take-over transaction with MindHealth Biomed Inc.; and MindHealth BioMed Corp.’s $9.3M non-brokered common share and subscription receipt private placements.
 - StageZero Life Sciences Ltd. in its $7.2M public offering of 9,243,700 units. Each Unit was comprised of one common share and one-half of one common share purchase warrant.
 - Orford Mining Corp. in its closing of a $5.25M non-brokered private placement of: flow-through units at an issue price of C$0.315 per unit, and hard dollar units at an issue price of C$0.18 per unit.
 - Hemlo Explorers Inc. in its closing of a fully-subscribed $3.5M non-brokered private placement.
 - Kontrol Energy Corp. in its $2.7M acquisition of New Found Air, paid as $1.55 Million in cash, $750,000 vendor take-back loan having performance conditions, and the issuance of 727,272 Kontrol common shares at a deemed price of $0.55 cents per share.
 - Kontrol Energy Corp. in its $2M private placement of Units, each of which consisted of one $1,000 8% unsecured convertible debenture and 1,000 warrants.
 - StageZero Life Sciences Ltd. in its $4.6M public offering.
 - Antibe Therapeutics in its $28.75M bought deal public offering.
 - Canadian Orebodies Inc., a junior natural resource exploration and development company with a number of mineral properties located in Canada, in its acquisition of Hemlo Area Properties from O3 Mining Inc.
 - Kontrol Energy Corp., developer of smart energy solutions and technologies, in the $3.4-million acquisition of CEM Specialities Inc., a leading integrator of turn-key emission monitoring equipment and solutions.
 - Antibe Therapeutics Inc. in a $5.75-million bought deal public offering of 23,000,000 units of the Company at a price of $0.25 per Unit.
 - Pelangio Exploration in a non-brokered $750,000 private placement.
 - Pelangio Exploration in its acquisition of 2522962 Ontario Inc. (5SD Capital), a private company engaged in the trading and exploring of Canadian mineral properties.
 - Pelangio Exploration in a non-brokered $1,200,000 private placement of units.